The latest price target for Skye Bioscience (NASDAQ:SKYE) was reported by Piper Sandler on September 20, 2024. The analyst firm set a price target for $20.00 expecting SKYE to rise to within 12 months (a possible 523.05% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Skye Bioscience (NASDAQ:SKYE) was provided by Piper Sandler, and Skye Bioscience reiterated their overweight rating.

There is no last upgrade for Skye Bioscience

There is no last downgrade for Skye Bioscience.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Skye Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Skye Bioscience was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Skye Bioscience (SKYE) rating was a reiterated with a price target of $20.00 to $20.00. The current price Skye Bioscience (SKYE) is trading at is $3.21, which is out of the analyst’s predicted range.